Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals, Inc. on December 3, 2009, reporting events occurring on December 1, 2009. The filing addresses Item 5.02 regarding the appointment of a new Chief Financial Officer and the departure of the Acting Principal Financial Officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
- Appointment: Kathryn Falberg was appointed Senior Vice President and Chief Financial Officer, effective December 1, 2009.
- Departure: Joan E. Colligan stepped down as Acting Principal Financial Officer effective December 1, 2009, though she remains Controller and Principal Accounting Officer.
Compensation and Management Commentary
Ms. Falberg's compensation package includes:
- Base Salary: $365,000 per year.
- Hiring Bonus: $30,000.
- Annual Bonus: Targeted at 40% of base salary, contingent on corporate objectives.
- Equity: Option to purchase 100,000 shares of common stock under the 2007 Equity Incentive Plan. Vesting occurs over four years (25% after one year, remainder monthly).
- Change in Control: Full acceleration of equity vesting if terminated without cause or constructively within 12 months following or one month prior to a change in control.
- Severance: Eligible for the Executive Change in Control and Severance Benefit Plan, including a lump sum payment (generally 15 months of salary and bonus) and 15 months of COBRA premiums if terminated without cause within 12 months post-change in control.
Investor Verification Checklist
- Verify the full terms of the Offer Letter filed as Exhibit 10.92.
- Review the 2007 Equity Incentive Plan and the specific Option Agreement for detailed vesting schedules.
- Examine the Amended and Restated Executive Change in Control and Severance Benefit Plan for specific conditions regarding severance eligibility.
- Confirm the transition of financial reporting responsibilities from Joan E. Colligan to Kathryn Falberg.